Clinical Trials
11 trialsNCT04113863 2025-12-18
ATRA
Mario Negri Institute for Pharmacological Research
Phase 2 Terminated
NCT02712905 2025-11-04
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04700176 2025-02-25
A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma
Hackensack Meridian Health
Phase 2 Terminated
NCT04282668 2024-12-09
A Study of TAS1440 With ATRA in Subjects With r/r AML
Taiho Oncology, Inc.
Phase 1 Terminated
NCT02942758 2024-05-08
AML-ViVA
University Hospital Regensburg
Phase 2 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02641782 2022-11-04
NB2013-HR
University of Cologne
Phase 2 Terminated
NCT01985477 2016-09-14
Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00528450 2016-01-29
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00006220 2013-02-06
Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy
Washington University School of Medicine
Phase 1/2 Terminated
NCT00533169 2011-12-15
ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma
M.D. Anderson Cancer Center
Phase 1 Terminated